Clinical trials: Anal Carcinoma, open to volunteers
HPV Infection, Anal Cancer
Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial.
- Trial name
- HPVsign (NCT06522256)
- Testing
- High-resolution anoscopy
- Where
- 3 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Anal Cancer
A Study Regarding Tissue Response During and After Treatment for Anal Cancer
The aim of this study is to improve the understanding for the tumour biology in relation to treatment response in patients with anal cancer by examining: The tumour microenvironment The localisation of and cellular interactions…
- Trial name
- ANCABio (NCT05939401)
- Testing
- Biopsies
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Head and Neck Cancer, Ovarian Cancer
Deciphering Mechanisms Underlying Cancer Immunogenicity
This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors.
- Conditions
- Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3
- Trial name
- DECIDE (NCT03958240)
- Testing
- Blood samples, tumor biopsy specimens and ascites samples will be collected.
- Where
- 3 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Institut Claudius Regaud
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.